OncologyFDA Approved

Histrelin (Vantas)

Subcutaneous implant

Overview

Histrelin is a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH) that functions as a GnRH agonist. The peptide is administered via a subcutaneous implant that delivers continuous drug release over 12 months, inducing initial gonadotropin stimulation followed by sustained receptor downregulation and suppression of testicular androgen production.

Mechanism of Action

It is indicated for palliative treatment of advanced prostate cancer and management of central precocious puberty. Amino acid modifications at positions 6 and 10 enhance receptor binding and resistance to peptidase degradation..

Research Summary & Key Findings

Histrelin acetate received FDA approval in 2004 (Vantas implant for prostate cancer) and 2007 (Supprelin LA for central precocious puberty). Pivotal phase 3 trials demonstrated that over 90% of patients achieved and maintained castrate testosterone levels throughout the 52-week implant duration. The implant delivery system offers the advantage of eliminating the need for monthly or quarterly injections, improving adherence in long-term androgen deprivation therapy.

Clinical Status

FDA Approved

Histrelin (Vantas) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Subcutaneous implant

Related Peptides in Oncology

Carfilzomib (Kyprolis)

FDA Approved

A tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds the chymotrypsin-like (beta5) subunit of the 20S...

View details

Bortezomib (Velcade)

FDA Approved

A modified dipeptidyl boronic acid that reversibly inhibits the chymotrypsin-like activity of the 26S proteasome. Bortez...

View details

Lutetium-177 dotatate (Lutathera)

FDA Approved

A radiolabeled somatostatin analog consisting of the peptide DOTA-Tyr3-octreotate chelated to the beta-emitting radioiso...

View details

Leuprolide (Lupron) - Oncology

FDA Approved

A GnRH agonist used in oncology for androgen deprivation therapy (ADT) in prostate cancer and hormone suppression in pre...

View details

Find a Provider

Find a verified provider who offers Histrelin (Vantas) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Histrelin (Vantas).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.